B. Braun Medical Inc – FDA 483, Dec 15, 2023
An FDA inspection of B. Braun Medical Inc. in Irvine, CA, revealed significant deficiencies in quality control and manufacturing practices. Observations included a failure to thoroughly investigate out-of-specification results for Heparin Sodium, inadequate annual product review procedures, and non-adherence to written testing protocols for subvisible particulate matter. These issues indicate a need for improved quality system oversight and procedural compliance at the sterile drug manufacturing facility.
ID · 20548a71-1584-4d2e-af2e-edba60893864
- 483 - 2025-11-21
- 483 - 2020-07-23
- 483 - 2018-06-29
- EIR - 2016-05-11
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.